Rhumbline Advisers Sells 11,329 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Rhumbline Advisers lessened its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 7.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 150,162 shares of the company's stock after selling 11,329 shares during the period. Rhumbline Advisers owned 0.30% of Prestige Consumer Healthcare worth $12,909,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Kayne Anderson Rudnick Investment Management LLC bought a new position in Prestige Consumer Healthcare in the 4th quarter valued at $84,932,000. Raymond James Financial Inc. purchased a new stake in shares of Prestige Consumer Healthcare in the fourth quarter worth $42,593,000. Norges Bank bought a new stake in Prestige Consumer Healthcare during the fourth quarter valued at $40,009,000. Bessemer Group Inc. grew its position in Prestige Consumer Healthcare by 10,053.1% during the fourth quarter. Bessemer Group Inc. now owns 295,050 shares of the company's stock worth $23,041,000 after buying an additional 292,144 shares in the last quarter. Finally, Natixis Advisors LLC increased its stake in Prestige Consumer Healthcare by 1,335.1% in the 4th quarter. Natixis Advisors LLC now owns 209,246 shares of the company's stock worth $16,340,000 after acquiring an additional 194,665 shares during the last quarter. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Stock Down 0.3%

PBH traded down $0.28 during trading on Wednesday, hitting $86.36. 66,871 shares of the company's stock traded hands, compared to its average volume of 298,470. The stock has a market capitalization of $4.27 billion, a price-to-earnings ratio of 20.23, a PEG ratio of 2.69 and a beta of 0.45. The company's 50 day simple moving average is $83.56 and its two-hundred day simple moving average is $82.54. Prestige Consumer Healthcare Inc. has a 12-month low of $63.79 and a 12-month high of $90.04. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The firm had revenue of $296.52 million for the quarter, compared to analysts' expectations of $289.36 million. During the same period in the prior year, the firm earned $1.02 EPS. The company's revenue was up 7.0% compared to the same quarter last year. Analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on PBH. Oppenheimer lifted their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a research report on Thursday, February 13th. Wall Street Zen raised shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, May 17th. Finally, Royal Bank of Canada upgraded shares of Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.